Kyowa Kirin Co Ltd (Kyowa Kirin) focuses on the discovery, development and commercialization of pharmaceuticals and biotechnology products with focus on nephrology, central nervous system, oncology, immunology and allergy. The company operates through a single reporting segment: Pharmaceuticals business. It reports its revenue through two product categories: Products and Licenses. The pharmaceutical business focuses on R&D, manufacturing and commercialization of ethical drugs and diagnostic reagents. It offers pharmaceuticals for the therapeutic areas of oncology, nephrology and immunology/allergy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kyowa Kirin invests in the development of new and advanced drugs including antibodies, small molecules and nucleic acids and strives to improve wellness and treat disease with a special focus on nephrology, oncology, immunology and allergy, and central nervous system. It also focuses on nephrology, immunology and allergy, oncology and central nervous system. Major technology platforms include its Potelligent antibody technology and Complegent antibody-dependent cellular cytotoxicity (ADCC) enhancing technology. In FY2023, it spent JPY72,106 million representing a growth of 14.6% on its R&D related activities.